Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2026-02-09 Proxy Solicitation & In…
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Notice of General Meeting/Proxy Form 17 pages 465.1KB
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a Notice of General Meeting and Proxy Form for Neurotech International Limited, dated 10 February 2026, for a meeting scheduled on 12 March 2026. It includes detailed information about the meeting logistics, voting procedures, resolutions to be considered (such as ratification of placement shares and director participation in placements), and voting prohibitions and exclusions. The content is focused on informing shareholders about the meeting and soliciting their votes, rather than presenting financial results or management analysis. It is not a report or financial statement but a formal meeting notice and proxy solicitation document. Therefore, the document fits the category of Proxy Solicitation & Information Statement (PSI).
2026-02-09 English
Approval received for NTI164 Phase 3 Clinical Study in ASD 2 pages 239.5KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 February 2026 regarding the approval received for a Phase 3 clinical study of NTI164 in Autism Spectrum Disorder (ASD). It discusses regulatory approvals, study design, and plans for clinical trial initiation. There is no financial data, earnings information, or detailed financial statements. The content is an update on a clinical trial approval and regulatory milestone, which fits the category of a general regulatory announcement rather than a financial report or management discussion. It is not a report publication announcement since it does not mention the release or availability of a report, nor is it a certification or insider dealing. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and compliance updates that do not fit other specific categories.
2026-02-01 English
Quarterly Activities/Appendix 4C Cash Flow Report 8 pages 350.9KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Activities Report for the period ending 31 December 2025' and includes detailed operational highlights, R&D updates, corporate activities, and financial commentary. It also contains an Appendix 4C Quarterly Cash Flow Report, which is a regulatory requirement for Australian listed companies to report quarterly cash flows. The document provides substantive financial data such as cash operating expenses, cash inflows, cash and cash equivalents, and payments to related parties. The presence of detailed financial statements and analysis for a quarter (Q2 FY2026) indicates this is a comprehensive interim/quarterly report rather than a brief announcement or a simple regulatory filing. The document length (15,000 characters) and content depth confirm it is not merely an announcement of a report but the report itself. Therefore, the appropriate classification is Interim / Quarterly Report (IR). Q2 2026
2026-01-29 English
PANS Data Published in Leading Scientific Journal 2 pages 257.0KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 15 January 2026 from Neurotech International Limited. It announces the publication of clinical and mechanistic data for its drug NTI164 in a peer-reviewed scientific journal. The content focuses on the scientific and clinical trial results and the significance of the publication. There is no detailed financial data, no regulatory filing forms, no management or board changes, no voting results, no earnings or interim report data, and no capital or financing updates. The document is a public announcement about the publication of scientific data rather than a financial or regulatory report. It is not a report itself but an announcement of a publication. Given the length (5702 characters) and the nature of the content, it fits best as a Regulatory Filing (RNS) because it is a general regulatory announcement that does not fit into other specific categories such as earnings release or annual report. Therefore, the classification is Regulatory Filings (RNS) with high confidence.
2026-01-14 English
Application for quotation of securities - NTI 6 pages 18.3KB
Share Issue/Capital Change Classification · 100% confidence The document is titled 'Appendix 2A - Application for quotation of securities' and is an announcement by Neurotech International Limited regarding the application for quotation of securities on the ASX. It references a previous Appendix 3B announcement about the proposed issue of securities. The document details the number and type of securities to be quoted, issue dates, and issued capital following quotation. This is a formal application to list newly issued securities on the exchange, not a report of financial results, management discussion, or other report types. It is a regulatory announcement related to capital market activities but specifically an application for quotation of securities, which aligns with announcements about share issues or capital changes. Therefore, the most appropriate classification is 'Share Issue/Capital Change' (SHA). The document length and content confirm it is not a brief report publication announcement or a certification, but a substantive announcement about capital changes.
2025-12-23 English
Secondary Trading Notice 1 page 68.3KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 24 December 2025. It is titled 'Secondary Trading Notice Pursuant to Section 708A(5)(e) of the Corporations Act' and discusses the issuance of ordinary fully paid shares without disclosure under Part 6D.2 of the Corporations Act. The notice confirms compliance with relevant sections of the Corporations Act and states there is no excluded information to disclose. The document is short (2737 characters) and serves as a regulatory notice about share issuance rather than a full financial report or detailed capital update. It does not contain financial statements or detailed analysis but is a formal announcement related to capital changes. According to the filing definitions, announcements about new share issues or capital changes fall under 'Share Issue/Capital Change' (SHA). Therefore, the appropriate classification is SHA with high confidence.
2025-12-23 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.